Pre Close Update

Stanelco PLC 14 January 2008 14 January 2008 Stanelco plc ('Stanelco' or 'the Company') Pre Close Update Further to the Trading Statement of 29 May 2007 and the Interim Statement of 10 September 2007, the Board announces that the Company is expected to report a loss in line with market expectations. Sales growth has lagged forecast but this has been offset by the continued focus on careful cost and cash management, which has resulted in a cash position that is ahead of previous expectations. The Company's cash balance at the 2007 year-end close was £8.0m, which will provide greater resource for the commercialisation of the Company's technology. Stanelco BioPlastics The Board has strengthened this unit with the appointment in October 2007 of Paul Law as Managing Director. Paul has a research and development background in natural polymer chemistry and more recently a track record in the commercialisation of innovative polymer products. He is already increasing the commercial focus as we look to build revenues in this area of our business. Whilst there continues to be considerable interest from potential customers, some obstacles remain in commercialising bioplastics as reported previously. To help meet the requirements of this developing market, the Company is installing pilot extrusion and testing facilities at its UK base in Southampton during Q1 2008. Biotec Growth in the Biotec subsidiary has continued but at a slower rate than anticipated. Satisfactory progress is being made towards assuaging the previously reported patent challenges. Stanelco RF Applications The RF business continues to trade in line with expectations. We have increased our contact with our existing customer base and this has resulted in a growing number of customer enquiries particularly in the fibre optic furnace areas. A detailed business update will be provided at the Preliminary Results on the 14th March 2008. - Ends - For further information please contact: Jonathon Brill / Caroline Stewart Financial Dynamics Tel: +44 (0)20 7831 3113 This information is provided by RNS The company news service from the London Stock Exchange MG
UK 100